TOP2A and breast cancer: This finding suggests at least two things: one is that TOP2A is a prognostic factor for early stage luminal breast cancer treated with adjuvant endocrine therapy alone; another is that TOP2A might be a predictive factor for benefit from adjuvant chemotherapy.